Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Evaluation of Early Administration of Insulin Glargine in the Acute Management of Diabetic Ketoacidosis

Author(s): Adham Mohamed*, Jeannette Ploetz and Majdi S. Hamarshi

Volume 17, Issue 8, 2021

Published on: 03 March, 2021

Article ID: e030221191986 Pages: 8

DOI: 10.2174/1573399817666210303095633

Abstract

Background: Few studies have evaluated the early use of insulin glargine in the management of diabetic ketoacidosis (DKA) patients. Early insulin glargine use in DKA was safe and associated with a trend towards faster DKA resolution.

Objectives: To evaluate the efficacy and safety of early insulin glargine administration for acute management of DKA in critically ill patients.

Methods: This single-center retrospective cohort study included patients, who were >18 years of age with DKA, admitted to the intensive care unit (ICU) for at least 12 h, and received intravenous insulin infusion for at least 6 h. The primary endpoint was the association between the time to insulin glargine administration and time to DKA resolution. Linear and logistic regression analyses were performed.

Results: Of the 913 patients evaluated, 380 were included in the study. The overall mean age was 45±17 years, 196 (51.6%) were female, and 262 (70%) patients had type 1 diabetes mellitus. The mean blood glucose level was 584.9±210 mg/dL, pH was 7.16±0.17, anion gap was 28.17±6.9 mEq/L, and serum bicarbonate level was 11.19±5.72 mEq/L. Every 6-h delay in insulin glargine administration was associated with a 26-min increase in time to DKA resolution (95% confidence interval [CI], 14.76-37.44; p<0.0001), 3.2-h increase in insulin infusion duration (95% CI, 28.8-36; p<0.0001), and 6.5-h increase in ICU LOS (95% CI, 5.04-7.92; p<0.0001).

Conclusion: Early administration of insulin glargine is potentially safe and may be associated with a reduction in time to DKA resolution and a shorter duration of insulin infusion.

Keywords: Diabetes mellitus, diabetic ketoacidosis, insulin, insulin glargine, blood glucose, length of stay, retrospective study.

[1]
Centers for Disease Control and Prevention National Diabetes Statistics Report 2017. [Cited: 19 August 2019] Available from:. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html 19 August 2019
[2]
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018; 41(5): 917-28.
[http://dx.doi.org/10.2337/dci18-0007] [PMID: 29567642]
[3]
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32(7): 1335-43.
[http://dx.doi.org/10.2337/dc09-9032] [PMID: 19564476]
[4]
Benoit SR, Zhang Y, Geiss LS, et al. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality — United States, 2000-2014. MMWR Morb Mortal Wkly Rep 2018 March; 30; 67(12): 362-5.
[5]
Cunningham AM, Freeman AM. Glargine Insulin. StatPearls Treasure Island (FL) StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557756/ January 16, 2021
[6]
Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004; 27(8): 1873-8.
[http://dx.doi.org/10.2337/diacare.27.8.1873] [PMID: 15277410]
[7]
Della Manna T, Steinmetz L, Campos PR, et al. Subcutaneous use of a fast-acting insulin analog: An alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 2005; 28(8): 1856-61.
[http://dx.doi.org/10.2337/diacare.28.8.1856] [PMID: 16043723]
[8]
Ersöz HO, Ukinc K, Köse M, et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract 2006; 60(4): 429-33.
[http://dx.doi.org/10.1111/j.1368-5031.2006.00786.x] [PMID: 16620355]
[9]
Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev 2016; (1): CD011281.
[http://dx.doi.org/10.1002/14651858.CD011281.pub2] [PMID: 26798030]
[10]
Andrade-Castellanos CA, Colunga-Lozano LE. Systematic review with meta-analysis: Subcutaneous insulin glargine coadministration for diabetic ketoacidosis. Gac Med Mex 2016; 152(6): 761-769 [Article in Spanish]..
[PMID: 27861474]
[11]
Barski L, Brandstaetter E, Sagy I, Jotkowitz A. Basal insulin for the management of diabetic ketoacidosis. Eur J Intern Med 2018; 47: 14-6.
[http://dx.doi.org/10.1016/j.ejim.2017.08.025] [PMID: 28864157]
[12]
Doshi P, Potter AJ, De Los Santos D, Banuelos R, Darger BF, Chathampally Y. Prospective randomized trial of insulin glargine in acute management of diabetic ketoacidosis in the emergency department: A pilot study. Acad Emerg Med 2015; 22(6): 657-62.
[http://dx.doi.org/10.1111/acem.12673] [PMID: 26013711]
[13]
Houshyar J, Bahrami A, Aliasgarzadeh A. Effectiveness of insulin glargine on recovery of patients with diabetic ketoacidosis: A randomized controlled trial. J Clin Diagn Res 2015; 9(5): OC01-5.
[http://dx.doi.org/10.7860/JCDR/2015/12005.5883] [PMID: 26155506]
[14]
Hsia E, Seggelke S, Gibbs J, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab 2012; 97(9): 3132-7.
[http://dx.doi.org/10.1210/jc.2012-1244] [PMID: 22685233]
[15]
Shankar V, Haque A, Churchwell KB, Russell W. Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children. Intensive Care Med 2007; 33(7): 1173-8.
[http://dx.doi.org/10.1007/s00134-007-0674-3] [PMID: 17508198]
[16]
Harrison VS, Rustico S, Palladino AA, Ferrara C, Hawkes CP. Glargine co-administration with intravenous insulin in pediatric diabetic ketoacidosis is safe and facilitates transition to a subcutaneous regimen. Pediatr Diabetes 2017; 18(8): 742-8.
[http://dx.doi.org/10.1111/pedi.12462] [PMID: 27807910]
[17]
Savage MW, Dhatariya KK, Kilvert A, et al. Joint British Diabetes Societies. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med 2011; 28(5): 508-15.
[http://dx.doi.org/10.1111/j.1464-5491.2011.03246.x] [PMID: 21255074]
[18]
Ullal J, Aloi JA, Reyes-Umpierrez D, et al. Comparison of computer-guided versus standard insulin infusion regimens in patients with diabetic ketoacidosis. J Diabetes Sci Technol 2018; 12(1): 39-46.
[http://dx.doi.org/10.1177/1932296817750899] [PMID: 29291648]
[19]
Ullal J, McFarland R, Bachand M, Aloi J. Use of a computer-based insulin infusion algorithm to treat diabetic ketoacidosis in the Emergency Department. Diabetes Technol Ther 2016; 18(2): 100-3.
[http://dx.doi.org/10.1089/dia.2015.0215] [PMID: 26783996]
[20]
Desai D, Mehta D, Mathias P, Menon G, Schubart UK. Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: A nationwide analysis. Diabetes Care 2018; 41(8): 1631-8.
[http://dx.doi.org/10.2337/dc17-1379] [PMID: 29773640]
[21]
Rappaport SH, Endicott JA, Gilbert MP, Farkas JD, Clouser RD, McMillian WD. A Retrospective Study of Early vs Delayed Home Dose Basal Insulin in the Acute management of Diabetic Ketoacidosis. J Endocr Soc 2019; 3(5): 1079-86.
[http://dx.doi.org/10.1210/js.2018-00400] [PMID: 31069278]
[22]
Vidyasagar K, Chandrasekar B, Chhabra M, Bhansali A, Bansal D. Efficacy and SAfety of Commonly Used Insulin Analogues in the Treatment of DIabetic Ketoacidosis: A Bayesian Indirect Treatment Comparison. Clin Ther 2020; 42(8): e115-39.
[http://dx.doi.org/10.1016/j.clinthera.2020.06.017] [PMID: 32798057]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy